These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30348399)

  • 1. Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor.
    AlRabiah H; Hamidaddin MA; Darwish IA
    Talanta; 2019 Jan; 192():331-338. PubMed ID: 30348399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of generic heterogeneous fluoroimmunoassay for bioanalysis of bevacizumab and cetuximab monoclonal antibodies used for cancer immunotherapy.
    Hamidaddin MA; AlRabiah H; Darwish IA
    Talanta; 2018 Oct; 188():562-569. PubMed ID: 30029413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and comparative evaluation of two immunoassay platforms for bioanalysis of crizotinib: A potent drug used for the treatment of non-small cell lung cancer.
    Hamidaddin MA; AlRabiah H; Darwish IA
    Talanta; 2019 Aug; 201():217-225. PubMed ID: 31122414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors.
    Darwish IA; Alahmad W; Vinoth R
    Heliyon; 2024 May; 10(10):e31317. PubMed ID: 38803937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel automated flow-based immunosensor for real-time measurement of the breast cancer biomarker CA15-3 in serum.
    Darwish IA; Wani TA; Khalil NY; Blake DA
    Talanta; 2012 Aug; 97():499-504. PubMed ID: 22841114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic-exclusion analysis-based immunosensors versus enzyme-linked immunosorbent assays for measurement of cancer markers in biological specimens.
    Darwish IA; Wani TA; Alanazi AM; Hamidaddin MA; Zargar S
    Talanta; 2013 Jul; 111():13-9. PubMed ID: 23622520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma.
    Chiu HH; Tsai IL; Lu YS; Lin CH; Kuo CH
    Anal Bioanal Chem; 2017 Nov; 409(28):6583-6593. PubMed ID: 28963670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Comparative Evaluation of Two Highly Sensitive Immunosensor Platforms for Trace Determination of Copper Ions in Drinking Water Using a Monoclonal Antibody Specific to Copper-EDTA Complex.
    Darwish IA; Wang Z; Darling RJ
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.
    Iwamoto N; Takanashi M; Shimada T; Sasaki J; Hamada A
    AAPS J; 2019 Aug; 21(6):101. PubMed ID: 31432293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer.
    Urban H; Maurer GD; Luger AL; Lorenz NI; Sauer B; Stroh C; Trojan J; Mittelbronn M; Steinbach JP; Harter PN; Ronellenfitsch MW
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
    Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
    Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.
    Suárez I; Salmerón-García A; Cabeza J; Capitán-Vallvey LF; Navas N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():155-164. PubMed ID: 27296731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of two highly sensitive and selective sensor-assisted fluorescence immunoassays for trace determination of copper residues in food samples.
    Darwish IA; Wang Z; Darling RJ; Alzoman NZ
    RSC Adv; 2023 Oct; 13(42):29195-29205. PubMed ID: 37818275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of two different formats of heterogeneous fluorescence immunoassay for bioanalysis of afatinib by employing fluorescence plate reader and KinExA 3200 immunosensor.
    Darwish IA; AlRabiah H; Hamidaddin MA
    Sci Rep; 2019 Oct; 9(1):14742. PubMed ID: 31611565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
    Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
    Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical Application of Flow Immunosensor in Detection of Thyroxine and Triiodothyronine in Serum.
    Wani TA; Zargar S; Majid S; Darwish IA
    Assay Drug Dev Technol; 2016 Nov; 14(9):535-542. PubMed ID: 27801595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies.
    van Rosmalen M; Ni Y; Vervoort DFM; Arts R; Ludwig SKJ; Merkx M
    Anal Chem; 2018 Mar; 90(5):3592-3599. PubMed ID: 29443503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.